European Nuclear Medicine/Radiopharmaceuticals Market is Valued at USD 1.095 Billion in 2015

Date: 2015-11-09

The European nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and country. The European nuclear medicine/radiopharmaceuticals market is valued at USD 1.095 billion in 2015 and is poised to grow at a CAGR of 8.2% during the forecasted period. 

Factors such as increasing preference for SPECT and PET scans, advances in radiotracers, advent of alpha radio immunotherapy-based targeted cancer treatment, increasing incidence & mortality rate of cancer and cardiac ailments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, cyclotron based production are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, competition from conventional diagnostic procedures are hindering the growth of this market.

Some of the major players in the European nuclear medicine/radiopharmaceuticals market include Cardinal Health Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample